{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:47:14Z","timestamp":1787010434221,"version":"build-2736575974"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.euf.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,7,15]],"date-time":"2018-07-15T16:55:29Z","timestamp":1531673729000},"page":"503-505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Combination Intravesical Chemotherapy for Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"4","author":[{"given":"Ryan L.","family":"Steinberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2018.07.005_bib0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0022-5347(17)40882-2","article-title":"Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder","volume":"141","author":"Fukui","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.005_bib0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2016.03.034","article-title":"Intravesical bacillus Calmette-Gu\u00e4rin versus combination of epirubicin and interferon-\u00e92a in reducing recurrence of non?muscle-invasive bladder carcinoma: FinnBladder-6 study","volume":"70","author":"Marttila","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.005_bib0015","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.juro.2013.11.005","article-title":"5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guerin with epirubicin and interferon-alpha2b in patients with T1 bladder cancer","volume":"191","author":"Hemdan","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.005_bib0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.urolonc.2010.06.012","article-title":"A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer","volume":"30","author":"Chen","year":"2012","journal-title":"Urol Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.euf.2018.07.005_bib0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-5347(18)33076-3","article-title":"840: Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer","volume":"175","author":"Maymi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.005_bib0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"35","key":"10.1016\/j.euf.2018.07.005_bib0035","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.07.005_bib0040","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","article-title":"Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.07.005_bib0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"Suppl 15","key":"10.1016\/j.euf.2018.07.005_bib0050","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1200\/JCO.2017.35.15_suppl.4546","article-title":"Oncological outcomes of intravesical gemcitabine and docetaxel for select patients with high grade recurrent NMIBC","volume":"35","author":"Milbar","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2018.07.005_bib0055","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/j.juro.2017.02.498","article-title":"MP15-13 A phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory non-muscle invasive urothelial carcinoma of the bladder","volume":"197","author":"DeCastro","year":"2017","journal-title":"J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918301718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918301718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:46:41Z","timestamp":1762498001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456918301718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S2405456918301718"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2018.07.005","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination Intravesical Chemotherapy for Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}